Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Applied Therapeutics Inc (NQ: APLT )

1.280 -0.010 (-0.78%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Applied Therapeutics Inc

< Previous 1 2 Next >
APPLIED THERAPEUTICS Investors Are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Regarding Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
APPLIED THERAPEUTICS Investors Are Encouraged to Contact Kaplan Fox &amp; Kilsheimer LLP Regarding Potential Securities Law Violations
NEW YORK - (NewMediaWire) - December 07, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”)... 
Via TheNewswire.com
Exposures Product Safety
APPLIED THERAPEUTICS Is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
APPLIED THERAPEUTICS Is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox &amp; Kilsheimer LLP
NEW YORK - (NewMediaWire) - December 06, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”)... 
Via TheNewswire.com
Exposures Product Safety
Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Applied Therapeutics, Inc. (APLT)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Kaplan Fox &amp; Kilsheimer LLP is Investigating Potential Securities Law Violations Against Applied Therapeutics, Inc. (APLT)
NEW YORK - (NewMediaWire) - December 05, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”)... 
Via TheNewswire.com
Exposures Product Safety
Kaplan Fox & Kilsheimer LLP is Investigating Applied Therapeutics, Inc. (APLT) for Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Kaplan Fox &amp; Kilsheimer LLP is Investigating Applied Therapeutics, Inc. (APLT) for Potential Securities Law Violations
NEW YORK - (NewMediaWire) - December 04, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”)... 
Via TheNewswire.com
Exposures Product Safety
Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Reports Third Quarter 2024 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics to Present at the 2024 UBS Global Healthcare Conference
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics to Participate in Upcoming Investor Conferences
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Reports Second Quarter 2024 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Added to Russell 3000® Index
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Reports First Quarter 2024 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Inc. (NASDAQ: APLT) Records 52-Week High Wednesday Morning
Via Investor Brand Network
Applied Therapeutics Announces $100 Million Private Placement
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic Galactosemia
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Reports Third Quarter 2023 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics to Present at the UBS Biopharma Conference 2023
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7
From Applied Therapeutics
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.